Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch GlobeNewswire October 21, 2025 Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central […]

— Sales of $18.6 billion — Net earnings of $1.6 billion, or $6.95 per share — Cash from operations of $3.7 billion and free cash flow of $3.3 billion — Returned $1.8 billion of cash to shareholders through dividends and share repurchases — Increased share repurchase authority by $2 billion to a total authorization of

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your Dow Inc. (NYSE:DOW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dow-inc-lawsuit-submission-form?prid=173199&wire=1&utm_campaign=18

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your Baxter International, Inc. (NYSE:BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ:MLTX) concerning possible violations of federal securities laws. On September 29, 2025, MoonLake announced that its experimental

(NASDAQ:CMND),(CNSX:CMND.CN),(CNSX:CMND),(Frankfurt:CWY0.F), Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient for the first cohort of its Phase I/IIa

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your Fluor Corporation (NYSE:FLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluor-corporation-lawsuit-submission-form?prid=173205&wire=1&utm_campaign=27

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=173206&wire=1&utm_campaign=9

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder GlobeNewswire October 21, 2025 Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your Fortinet, Inc. (NASDAQ:FTNT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortinet-inc-lawsuit-submission-form?prid=173202&wire=1&utm_campaign=15